Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Results Recap: Medtronic's Valiant Navion Earns FDA Approval Based On 30-Day Results

Executive Summary

Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition covers the week of Oct. 19 - Oct. 25, including trial announcements from Medtronic, iCAD, PharmaEngine, Inc., Nanobiotix SA, and Myriad Genetics.

You may also be interested in...



Recall Of Valiant Navion Could Cost Medtronic $40M

The company ordered the recall after three stent fractures and a death occurred in an 89-participant clinical trial.

2018 Earnings Spotlight: Transcatheter Valve Repair Remains Big Drivers For Medtronic, Edwards, Abbott

Reported sales and earnings from the publicly traded cardiovascular device companies in 2018 were generally strong, led by transcatheter aortic valve replacement devices, but some sectors of the industry, especially ventricular assist devices and peripheral drug-coated balloons, face significant challenges. Here's a recap of results from the cardio device companies that have reported so far, with a focus on Medtronic, Edwards, and Abbott.

Minute Insight: Titan Medical Cuts Costs As It Continues ‘Strategic Review’

The Canadian robotic surgery company is still working toward an FDA approval for its Enos single-access robotic surgery system, but is laying off 40 people in its Chapel Hill, NC, offices to save money.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT123490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel